{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:42:09Z","timestamp":1794606129591,"version":"4.9.1"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bruton tyrosine kinase (BTK) is a nonreceptor tyrosine kinase that plays a central role in the signal transduction of the B-cell antigen receptor and other cell surface receptors, both in normal and malignant B lymphocytes. B-cell antigen receptor signaling is activated in secondary lymphatic organs and drives the proliferation of malignant B cells, including chronic lymphocytic leukemia (CLL) cells. During the last 10 years, BTK inhibitors (BTKis) are increasingly replacing chemotherapy-based regimen, especially in patients with CLL and mantle cell lymphoma (MCL). Bruton tyrosine kinase inhibitors are particularly active in patients with CLL and MCL, but also received approval for Waldenstr\u00f6m macroglobulinemia, small lymphocytic lymphoma, marginal zone lymphoma, and chronic graft-versus-host disease. Current clinical practice is continuous long-term administration of BTKi, which can be complicated by adverse effects or the development of drug resistance. Alternatives to long-term use of BTKi are being developed, such as combination therapies, permitting for limited duration therapy. Second-generation BTKis are under development, which differ from ibrutinib, the first-in-class BTKi, in their specificity for BTK, and therefore may differentiate themselves from ibrutinib in terms of adverse effects or efficacy.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000412","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T01:32:50Z","timestamp":1574645570000},"page":"386-393","source":"Crossref","is-referenced-by-count":184,"title":["Bruton Tyrosine Kinase Inhibitors"],"prefix":"10.1097","volume":"25","author":[{"given":"Jan A.","family":"Burger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230924","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"bib2-20230924","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.immuni.2006.11.012","article-title":"Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing","volume":"26","year":"2007","journal-title":"Immunity"},{"key":"bib3-20230924","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2012-08-452607","article-title":"Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling","volume":"121","year":"2013","journal-title":"Blood"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1084\/jem.20011866","article-title":"The B cell antigen receptor controls integrin activity through BTK and PLCgamma2","volume":"198","year":"2003","journal-title":"J Exp Med"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.2013.53.1046","article-title":"Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1038\/onc.2016.343","article-title":"From identification of the BTK kinase to effective management of leukemia","volume":"36","year":"2017","journal-title":"Oncogene"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","year":"2010","journal-title":"Blood"},{"key":"bib10-20230924","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","year":"2014","journal-title":"Blood"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","year":"2012","journal-title":"Blood"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/blood-2009-03-212837","article-title":"B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor R406","volume":"114","year":"2009","journal-title":"Blood"},{"key":"bib13-20230924","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","year":"2012","journal-title":"Blood"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","year":"2011","journal-title":"Blood"},{"key":"bib15-20230924","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","year":"2018","journal-title":"Blood"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","year":"2015","journal-title":"JAMA Oncol"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","article-title":"Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"100","year":"2015","journal-title":"Haematologica"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1161\/ATVBAHA.115.306130","article-title":"Ibrutinib inhibits platelet integrin alphaiibbeta3 outside-in signaling and thrombus stability but not adhesion to collagen","volume":"35","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor\u2013dependent platelet functions","volume":"124","year":"2014","journal-title":"Blood"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/bjh.15690","article-title":"Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis","volume":"184","year":"2019","journal-title":"Br J Haematol"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","year":"2015","journal-title":"Blood"},{"key":"bib26-20230924","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1158\/1078-0432.CCR-16-1431","article-title":"Extended treatment with single-agent ibrutinib at the 420 mg dose leads to durable responses in chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"23","year":"2017","journal-title":"Clin Cancer Res"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2011-04-348656","article-title":"Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study","volume":"118","year":"2011","journal-title":"Blood"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia","volume":"28","year":"2010","journal-title":"J Clin Oncol"},{"key":"bib30-20230924","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","article-title":"Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia","volume":"133","year":"2019","journal-title":"Blood"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","year":"2019","journal-title":"Lancet Oncol"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","year":"2019","journal-title":"N Engl J Med"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"bib37-20230924","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood.V124.21.78.78","article-title":"Mutational analysis of patients with primary resistance to single-agent ibrutinib in relapsed or refractory mantle cell lymphoma (MCL)","volume":"124","year":"2014","journal-title":"Blood"},{"key":"bib38-20230924","doi-asserted-by":"crossref","first-page":"14920","DOI":"10.1038\/ncomms14920","article-title":"Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma","volume":"8","year":"2017","journal-title":"Nat Commun"},{"key":"bib39-20230924","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib40-20230924","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in Waldenstrom's macroglobulinemia","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib41-20230924","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1182\/blood.V128.22.1213.1213","article-title":"Single-agent ibrutinib demonstrates efficacy and safety in patients with relapsed\/refractory marginal zone lymphoma: a multicenter, open-label, phase 2 study","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib42-20230924","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): a covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile","volume":"363","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"bib43-20230924","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","year":"2016","journal-title":"N Engl J Med"},{"key":"bib44-20230924","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","year":"2018","journal-title":"Lancet"},{"key":"bib45-20230924","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton's tyrosine kinase","volume":"62","year":"2019","journal-title":"J Med Chem"},{"key":"bib46-20230924","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib47-20230924","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","article-title":"Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"key":"bib48-20230924","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib49-20230924","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood.V128.22.2032.2032","article-title":"First-in-human phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of the noncovalent bruton tyrosine kinase (BTK) inhibitor SNS-062 in healthy subjects","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib50-20230924","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","year":"2018","journal-title":"Blood"},{"key":"bib51-20230924","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/blood-2018-08-865659","article-title":"Ibrutinib and Aspergillus: a BTK-targeted risk","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib53-20230924","first-page":"833.e5","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","year":"2017","journal-title":"Cancer Cell"},{"key":"bib54-20230924","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-12-823393","article-title":"Ibrutinib blocks BTK-dependent NF-kB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib55-20230924","first-page":"189","article-title":"Anticancer drug-induced cardiac rhythm disorders: current knowledge and basic underlying mechanisms","volume":"189","year":"2018","journal-title":"Pharmacol Ther"},{"key":"bib56-20230924","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","year":"2017","journal-title":"Haematologica"},{"key":"bib57-20230924","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","article-title":"The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib58-20230924","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","year":"2017","journal-title":"Blood"},{"key":"bib59-20230924","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2018.06.002","article-title":"Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies","volume":"72","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"bib60-20230924","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","volume":"114","year":"2009","journal-title":"Blood"},{"key":"bib61-20230924","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","year":"2015","journal-title":"Nat Med"},{"key":"bib62-20230924","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","year":"2017","journal-title":"Blood"},{"key":"bib63-20230924","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1002\/cncr.29566","article-title":"Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens","volume":"121","year":"2015","journal-title":"Cancer"},{"key":"bib64-20230924","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"bib65-20230924","doi-asserted-by":"crossref","first-page":"11589","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","year":"2016","journal-title":"Nat Commun"},{"key":"bib66-20230924","doi-asserted-by":"crossref","first-page":"13906","DOI":"10.1073\/pnas.1409362111","article-title":"Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)","volume":"111","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib67-20230924","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1182\/blood-2017-01-761726","article-title":"Acquired mutations associated with ibrutinib resistance in Waldenstrom macroglobulinemia","volume":"129","year":"2017","journal-title":"Blood"},{"key":"bib68-20230924","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","year":"2014","journal-title":"Cancer Discov"},{"key":"bib69-20230924","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nature22353","article-title":"The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3beta inhibition","volume":"546","year":"2017","journal-title":"Nature"},{"key":"bib70-20230924","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","year":"2015","journal-title":"N Engl J Med"},{"key":"bib71-20230924","first-page":"498","article-title":"Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated results from the phase 1\/2 ACE-CL-001 study","volume":"130","year":"2017","journal-title":"Blood"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T01:14:14Z","timestamp":1695518054000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000412"}},"subtitle":["Present and Future"],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":69,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000412","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}